Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma

被引:11
|
作者
Lv, C. [1 ]
Li, X. J. [1 ]
Hao, L. X. [1 ]
Zhang, S. [2 ]
Song, Z. [3 ]
Ji, X. D. [1 ]
Gong, B. [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Dept Gastroenterol, Shuguang Hosp, 528 Zhangheng Rd, Shanghai 201203, Peoples R China
[2] Qiqihaer Jianhua Hosp, Dept Gastroenterol, Qiqihar 161000, Heilongjiang, Peoples R China
[3] Qiqihar First Hosp, Dept Gastroenterol, Qiqihar 161000, Heilongjiang, Peoples R China
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2022年 / 24卷 / 01期
关键词
Hepatocellular carcinoma (HCC); Elongation factor Tu GTP-binding domain containing 2 (EFTUD2); Survival prognosis; Cell cycle; RNA-BINDING PROTEINS; MANDIBULOFACIAL DYSOSTOSIS; U5; SNRNP; MUTATION; HAPLOINSUFFICIENCY; EPIDEMIOLOGY; REGULATOR; APOPTOSIS; DIAGNOSIS; REVEALS;
D O I
10.1007/s12094-021-02673-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Elongation factor Tu GTP-binding domain containing 2 (EFTUD2) is an essential constituent of U5 small nuclear ribonucleoproteins (snRNPs) and plays a crucial role in spliceosome activation and cancer. The mechanism of EFTUD2 on carcinogenesis and development of liver cancer still need further study. Methods Bioinformatic analysis was performed to find differential expressed genes and related pathways. Western blotting and quantitative PCR assays were used to verify the EFTUD2 expression in HCC cell lines and tumor tissues of liver cancer patients. Transfection of shRNAs in SKHEP1 and Huh7 cell lines was conducted to explore the mechanisms of EFTUD2 in HCC. CCK-8 method, colony formation, and cell cycle detection kit were used to detect the proliferation. A tumor model in nude mice was used to explore the role of EFTUD2 in liver cancer in vivo. Results Based on the tumor tissues and para-tumor tissues in our HCC patients, we identified EFTUD2 as highly expressed in HCC tissues (P < 0.001). Bioinformatic analysis from the TCGA database also supported this biological phenomenon (P = 1.911e-17). Furtherly, the results of clinical specimens and TCGA data suggested that higher EFTUD2 expression levels correlated with high histologic grades, high pathological grades, and poor survival prognoses in HCC patients. And knockdown of EFTUD2 suppressed cell proliferation and colony formation in vitro. In vivo, knockdown of EFTUD2 constrained the tumor growing and expansion derived from SKHEP1 cells and induced a decrease in the tumor volume and tumor weight resected from nude mice. Furthermore, RNA sequencing based on EFTUD2 knockdown revealed that EFTUD2 affected target genes concerned with the cell cycle. Flow cytometric analyses in the SKHEP1 cell model revealed that knockdown significantly suppressed cell cycle course and caused cell cycle arrest in the G1 phase. CyclinD1 proteins were also inhibited by knocking down of EFTUD2. Conclusion EFTUD2 is markedly overexpressed in HCC tumor tissues. High EFTUD2 expression in HCC patients is associated with clinical features. Moreover, we confirmed that EFTUD2 shows a pivotal role in HCC cell proliferation and cell cycle course and could be a possible therapeutic avenue in HCC through disturbing EFTUD2.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 50 条
  • [1] Over-activation of EFTUD2 correlates with tumor propagation and poor survival outcomes in hepatocellular carcinoma
    C. Lv
    X. J. Li
    L. X. Hao
    S. Zhang
    Z. Song
    X. D. Ji
    B. Gong
    Clinical and Translational Oncology, 2022, 24 : 93 - 103
  • [2] EFTUD2 MAINTAINS SURVIVAL OF TUMOR CELLS VIA JAK/STAT3 PATHWAY AND PREDICTS POOR OUTCOMES IN HEPATOCELLULAR CARCINOMA
    Tu, Mengxian
    Yuan, Hui
    Zheng, Dandan
    Xu, Yan
    Liu, Mingyu
    Lin, Zelong
    He, Lu
    Hu, Qiaoting
    Qu, Chen
    Hong, Jian
    HEPATOLOGY, 2019, 70 : 561A - 561A
  • [3] EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3
    Tu, Mengxian
    He, Lu
    You, Yang
    Li, Jinying
    Yao, Nan
    Qu, Chen
    Huang, Wei
    Xu, Leibo
    Luo, Rongcheng
    Hong, Jian
    CELL DEATH & DISEASE, 2020, 11 (10)
  • [4] EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3
    Mengxian Tu
    Lu He
    Yang You
    Jinying Li
    Nan Yao
    Chen Qu
    Wei Huang
    Leibo Xu
    Rongcheng Luo
    Jian Hong
    Cell Death & Disease, 11
  • [5] High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer
    Beyer, Susanne
    Mueller, Lena
    Mitter, Sophie
    Keilmann, Lucia
    Meister, Sarah
    Buschmann, Christina
    Kraus, Fabian
    Topalov, Nicole E.
    Czogalla, Bastian
    Trillsch, Fabian
    Burges, Alexander
    Mahner, Sven
    Schmoeckel, Elisa
    Loeb, Sanja
    Corradini, Stefanie
    Kessler, Mirjana
    Jeschke, Udo
    Kolben, Thomas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (08) : 4293 - 4303
  • [6] High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer
    Susanne Beyer
    Lena Müller
    Sophie Mitter
    Lucia Keilmann
    Sarah Meister
    Christina Buschmann
    Fabian Kraus
    Nicole E. Topalov
    Bastian Czogalla
    Fabian Trillsch
    Alexander Burges
    Sven Mahner
    Elisa Schmoeckel
    Sanja Löb
    Stefanie Corradini
    Mirjana Kessler
    Udo Jeschke
    Thomas Kolben
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 4293 - 4303
  • [7] EFTUD2 Regulates Invasion and Metastasis of Hepatocellular Carcinoma By Inducing Epithelial-Mesenchymal Transition
    Tu, Mengxian
    Liu, Mingyu
    Zheng, Dandan
    Hu, Qiaoting
    Yuan, Hui
    Chen, Peng
    Lin, Zelong
    Dai, Guanqi
    Song, Zhenghui
    Luo, Xiaojun
    He, Lu
    Qu, Chen
    Li, Aimin
    Hong, Jian
    HEPATOLOGY, 2018, 68 : 1277A - 1277A
  • [8] Abnormal platelet count correlates with poor survival in hepatocellular carcinoma
    Lei Gu
    Wen Wen
    Zhixian Wu
    Kai Bai
    Wei Liu
    Guoxiang Lai
    Dongliang Li
    InfectionInternational, 2017, 6 (03) : 91 - 100
  • [9] Transaldolase Deficiency in Hepatocellular Carcinoma Correlates With Poor Tumor Differentiation and Poor Prognosis
    Shirazi, Maryam
    Siegel, Abby
    Lefkowitch, Jay
    Salomao, Marcela
    MODERN PATHOLOGY, 2015, 28 : 424A - 424A
  • [10] Transaldolase Deficiency in Hepatocellular Carcinoma Correlates With Poor Tumor Differentiation and Poor Prognosis
    Shirazi, Matyam
    Siegel, Abby
    Lefkowitch, Jay
    Salomao, Marcela
    LABORATORY INVESTIGATION, 2015, 95 : 424A - 424A